Opendata, web and dolomites

Need2immune SIGNED

Personalized liposomal cancer vaccines within days by rapid formulation screening

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Need2immune project word cloud

Explore the words cloud of the Need2immune project. It provides you a very rough idea of what is the project "Need2immune" about.

modulators    drugs    localised    reactions    understand    tumour    transdermal    therapeutic    cancer    microneedles    lower    inject    administer    immunotherapeutic    trackable    locally    injected    doses    patients    toxicity    easily    host    personalised    injections    autoimmunity    period    immunotherapy    accelerate    levels    attracting    administered    mobilise    painlessness    bloodstream    checkpoint    mainstream    delivering    last    agents    combination    decrease    immune    kill    cells    microneedle    tools    drug    therapy    immunotherapies    systemic    cargo    use    onco    central    strategies    drawbacks    serious    serum    reagents    classes    unprecedented    harbours    mechanism    oncology    direct    clinical    adverse    molecules    risk    nanoparticles    eradication    ease    vaccine    autoimmune    sustained    shown    complete    causing    drastically    efficacy    intradermal    administration    play    anticipated    remissions    action    losing    possibility   

Project "Need2immune" data sheet

The following table provides information about the project.

Coordinator
TECODEVELOPMENT GMBH 

Organization address
address: MARIE-CURIE-STR. 1
city: RHEINBACH
postcode: 53359
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 162˙806 €
 EC max contribution 162˙806 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECODEVELOPMENT GMBH DE (RHEINBACH) coordinator 162˙806.00

Map

 Project objective

Cancer immunotherapy, defined as the ability to mobilise the host’s own immune system to kill cancer, has recently within the last 5 years, taken a central role within mainstream oncology. This period has seen the field rapidly accelerate towards unprecedented clinical responses in patients, and the development of novel classes of immunotherapeutic drugs. One approach has been to design more personalised immunotherapies along with new methods in delivering the therapeutic cargo. It is anticipated that this will play a defining role for cancer immunotherapy in terms of how to better achieve sustained remissions or complete eradication. One of the challenges in the future will be to understand how to administer these molecules since the current approach of systemic administration harbours the risk of causing serious toxicity and/or autoimmunity. This could drastically lower the serum levels of immune reagents needed with a decrease in adverse effects and lower risk of autoimmune reactions, without losing systemic efficacy. Currently, cancer immunotherapies are injected into the bloodstream but systemic injections have many drawbacks. It could be more effective therefore to inject this kind of therapy locally and directly to target tumour cells. This proposal will be to implement a more direct approach, where the immunotherapy's effects could be more easily controlled, with also the possibility for lower doses to be administered. Recently, microneedles have been attracting attention as new drug delivery tools. The microneedle has already been shown to be a highly effective intradermal and transdermal vaccine delivery method due to its mechanism of action, painlessness and ease of use. The goal is therefore to use microneedles to deliver localised doses of combination immunotherapies, e.g. vaccine with checkpoint modulators, in nanoparticles, as the focus of a novel approach to developing new strategies for the trackable delivery of onco-immunotherapeutic agents.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEED2IMMUNE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEED2IMMUNE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

COSMOS (2020)

The Conformation Of S-phase chroMOSomes

Read More  

COR1-TCELL (2019)

Analysis of the role for coronin 1-dependent cell density signalling in T-cell homeostasis

Read More  

GENESIS (2020)

unveilinG cEll-cell fusioN mEdiated by fuSexins In chordateS

Read More